Characteristic | Value |
---|---|
Age (years)a | 60.7 (40.7 to 76.2) |
Gender [cases (%)] | |
Men | 18 (72) |
Women | 7 (28) |
ECOG performance status [cases (%)] | |
0 | 10 (40) |
1 | 11 (44) |
2 | 4 (16) |
Underlying hepatitis [cases (%)] | |
B | 20 (80) |
C | 2 (8) |
Alcoholic | 1 (4) |
No hepatitis | 2 (8) |
Child-Pugh classification [cases (%)] | |
A | 19 (76) |
B | 6 (24) |
Tumor size (cm) a | 1.7 (0.7 to 16.3) |
GTV (cm3) a | 6.84 (0.72 to 114.7) |
T category [cases (%)] | |
1 | 1 (4) |
2 | 12 (48) |
3 | 12 (48) |
Pre-radiotherapy AFP concentration (IU/mL) a | 25.94 (1.42 to 34,132) |
AFP concentration change a | 0.9 (0.01 to 1,132.5) |
Total radiotherapy dose (Gy) a | 55.0 (40.0 to 60.0) |
Daily radiotherapy dose (Gy) a | 2.5 (2 to 4) |
Biologically equivalent dose (Gy10) a | 67.1 (56.0 to 78.0) |
Previous TACE [number of tumors (%)] | |
Yes | 23 (58.9) |
No | 16 (41.1) |
Interval between radiotherapy and TACE (months) a | 3.2 (0.5 to 13.0) |